Bristol-Myers Squibb struggled in the second quarter as its blood cancer treatment Revlimid, in particular, disappointed sales expectations. The pharma giant posted lower-than-expected earnings and lowered full-year guidance for 2023 in its financial results reported on Thursday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,